

Zhe Liu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3684552/zhe-liu-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

345
citations

10
h-index

18
g-index

42
ext. papers

484
ext. citations

2.8
avg, IF

3.36
L-index

#	Paper	IF	Citations
29	Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection.. <i>Technology in Cancer Research and Treatment</i> , 2022 , 21, 15330338221078438	2.7	0
28	Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.. <i>Diagnostic Pathology</i> , 2022 , 17, 27	3	0
27	Application of Rapid Rehabilitation Surgical Nursing Combined With Continuous Nursing in Self-Care Ability, Medication Compliance and Quality of Life of Renal Transplant Patients.. <i>Frontiers in Surgery</i> , 2022 , 9, 844533	2.3	0
26	Overexpression of fibrinogen-like protein 2 alleviates acute rejection in rat models of liver transplantation. <i>Annals of Translational Medicine</i> , 2021 , 9, 408	3.2	
25	Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases. <i>Frontiers in Oncology</i> , 2021 , 11, 622142	5.3	0
24	Granzyme B-Producing B Cells Function as a Feedback Loop for T Helper Cells in Liver Transplant Recipients with Acute Rejection. <i>Inflammation</i> , 2021 , 44, 2270-2278	5.1	2
23	ALK-rearranged squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2021 , 12, 1106-1114	3.2	5
22	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1403-1414	8.9	0
21	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study. <i>Lung Cancer</i> , 2020 , 146, 252-262	5.9	4
20	Overexpression of NNT-AS1 Activates TGF- Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2020 , 2020, 8216541	3	6
19	Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression. <i>Bioscience Reports</i> , 2020 , 40,	4.1	12
18	Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 149, 154-161	5.9	8
17	Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first-line chemotherapy: A multicenter prospective cohort study. <i>Thoracic Cancer</i> , 2020 , 11, 3641-3644	3.2	2
16	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , 2020 , 147, 259-268	5.9	9
15	Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14067-e14067	2.2	1
14	Tn antigen promotes human colorectal cancer metastasis via H-Ras mediated epithelial-mesenchymal transition activation. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 2083-2092	5.6	14
13	Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion. <i>Thoracic Cancer</i> , 2018 , 9, 298-304	3.2	9

12	T-Synthase Deficiency Enhances Oncogenic Features in Human Colorectal Cancer Cells via Activation of Epithelial-Mesenchymal Transition. <i>BioMed Research International</i> , 2018 , 2018, 9532389	3	10
11	Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 4875-4885	5.6	27
10	CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2018 , 40, 2023-2035	3.5	16
9	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018 , 7, 428-436	4.4	5
8	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1207-1217	2.2	17
7	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1743-1749	8.9	7
6	Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. <i>OncoTargets and Therapy</i> , 2017 , 10, 2289-2295	4.4	15
5	Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma. <i>Thoracic Cancer</i> , 2017 , 8, 8-15	3.2	10
4	Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo. <i>Oncotarget</i> , 2017 , 8, 3441-3453	3.3	47
3	MicroRNA-375 suppresses human colorectal cancer metastasis by targeting Frizzled 8. <i>Oncotarget</i> , 2016 , 7, 40644-40656	3.3	38
2	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. <i>Lung Cancer</i> , 2014 , 83, 231-9	5.9	78
1	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19149-e19149	7.2	79